Start-up and Emerging Companies to Present at BIO2017
San Diego, CA- June 12, 2017 – Objective Capital Partners, a leading M&A investment banking firm specializing in middle-market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a Judge for company finalists during live presentations as part of BIO 2017 Start-Up Stadium on June 20-22, 2017 in San Diego, CA. As the world’s largest biotechnology event, the BIO International Convention provides several specialized opportunities geared towards start-up and emerging companies. The Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees.
In 2017, applications were submitted from coast to coast across the United States and countries around the world. Applications were judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. The first panel of judges reviewed over 100 applications in order to establish the current pool of 40 highly-qualified finalists. For more information about Start-up Stadium and BIO 2017, please visit http://convention.bio.org/startup/ or contact Nareg Sagherian, Director, Investor Relations & Programming, Biotechnology Innovation Organization at nsagherian@bio.org or telephone 202.292.4666.
About BIO
Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association, represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. For more information, visit https://www.bio.org/.
About Objective Capital Partners
Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies. The firm focuses on middle market M&A and capital raise activities for companies with enterprise values between $10-100 million, healthcare & life sciences and valuation advisory services. The firm’s industry expertise includes software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Dr. Crean and other Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com.
Disclosure
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.
# # #
Objective Capital Partners Contact:
Mandy F. Woods
Business Office Manager
Objective Capital Partners
Tel: 858-208-3442
